Beyond Air, Inc. (XAIR)
| Market Cap | 5.36M |
| Revenue (ttm) | 6.92M |
| Net Income (ttm) | -31.00M |
| Shares Out | 10.53M |
| EPS (ttm) | -5.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 194,070 |
| Open | 0.490 |
| Previous Close | 0.487 |
| Day's Range | 0.488 - 0.515 |
| 52-Week Range | 0.430 - 5.842 |
| Beta | 0.53 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+1,864.25%) |
| Earnings Date | Jun 16, 2026 |
About XAIR
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for ... [Read more]
Financial Performance
In fiscal year 2025, Beyond Air's revenue was $3.71 million, an increase of 219.67% compared to the previous year's $1.16 million. Losses were -$46.63 million, -22.60% less than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for XAIR stock is "Strong Buy" and the 12-month stock price target is $10.0.
News
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients following a single intratumoral UNO injection
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (...
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th Data was published in the Online Itinerary Planner fo...
Beyond Air Transcript: Life Sciences Virtual Investor Forum
Nitric oxide delivery technology is expanding globally, with FDA and CE mark approvals and a second-generation system expected to drive further growth. Quarterly revenue rose 105% year-over-year, and international expansion is underway, with new clinical data in cancer to be presented soon.
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air Earnings Call Transcript: Q3 2026
Revenue doubled year-over-year to $2.2M, with strong hospital adoption and improved gross margin. Operating expenses and net loss declined significantly, and recent financings extend cash runway into 2027. Gen 2 LungFit PH approval is expected by end of 2026.
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash ...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
A novel nitric oxide delivery system offers safer, greener, and more cost-effective treatment, with a second-generation device set to drive U.S. and global market expansion. Robust R&D in infectious disease, cancer, and neurology, plus strong patent protection, support long-term growth.
XTL Biopharmaceuticals Acquires 85% of Beyond Air's Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease...
Beyond Air® Announces Transition of Chief Financial Officer
GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air Earnings Call Transcript: Q2 2026
Revenue surged 128% year-over-year to $1.8M in Q2 FY2026, with robust international expansion and a new capital purchase model introduced. Operating expenses and net loss declined significantly, and guidance was updated to $8–$10M for FY2026.
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, ...
Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
GARDEN CITY, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnes...
Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
GARDEN CITY, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnes...
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GARDEN CITY, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnes...
Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan
These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion people These recent LungFit PH international agreements bring the ex-U...
Beyond Air Earnings Call Transcript: Q1 2026
Q1 FY2026 revenue grew 157% year-over-year to $1.8M, driven by strong LungFit PH adoption and new contracts. Operating expenses and cash burn were significantly reduced, and FY2026 revenue guidance of $12M–$16M was reaffirmed, with international expansion accelerating.
Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., July 25, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.
GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harness...
Beyond Air Stock Dips After Mixed Q4 Results: Here's What To Know
Beyond Air, Inc. XAIR released its fourth-quarter results after Tuesday's closing bell. Here's a look at the key figures from the quarter.
Beyond Air Earnings Call Transcript: Q4 2025
Revenue surged 220% to $3.7M in FY2025, driven by U.S. hospital adoption and international expansion. FY2026 guidance is $12–$16M, with further cost reductions and new product launches expected to boost growth. Net loss narrowed and cash burn fell 28%.
Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and int...
Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH
LungFit PH II's smaller, lightweight, transport-ready design is expected to open the entirety of the NO market Final design based upon substantial feedback from respiratory therapists across the count...
Top Wall Street Forecasters Revamp Beyond Air Expectations Ahead Of Q4 Earnings
Beyond Air, Inc. XAIR will release its fourth-quarter financial results after the closing bell on Tuesday, June 17.